This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Statin Intolerance Medical Crossfire®: PCSK9 Inhibitors in Practice: Efficacy, Safety, Barriers, and Benefits—Segment 3

Statin Intolerance Medical Crossfire®: PCSK9 Inhibitors in Practice: Efficacy, Safety, Barriers, and Benefits—Segment 3

Format

Roundtable

Time to Complete

15 minutes

Released

June 29, 2017

Expires

June 29, 2018
Add to Queue


Maximum Credits

0.25 / AMA PRA Category 1 CreditTM
0.25 / CE for Nurse Practitioners

Accredited Provider

Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)

Commercial Supporter

Supported by an educational grant from Amgen.

Program Description

This activity is designed to update clinicians on the identification and diagnosis, as well as current guidelines and emerging algorithms, for the treatment of statin intolerant patients. The efficacy and safety of current and emerging therapies for statin intolerant patients will also be reviewed. Expert faculty will discuss the true incidence and diagnostic criteria of statin intolerance, the mechanistic rationale for lowering LDL-C through PCSK9 inhibition and other novel targets/pathways, treatment strategies, and where emerging therapies fit into current treatment guidelines and algorithms. Learners have the opportunity to gain a practical clinical perspective from an expert roundtable discussion on a statin intolerant patient case. This activity is expected to improve lipid management of patients at increased ASCVD risk, particularly those with statin intolerance. The discussions will demonstrate how clinicians approach patient cases and treatment decisions through their commentary, analysis, and recommendations for best practices in hypercholesterolemia.

This is the third of 4 activities in a 4-part series. Additional activities in this series are available at the bottom of this page under the Related Activities heading.

Intended Audience

Lipidology, cardiology, endocrinology, and primary care physicians, NPs, and other allied health professionals with an interest in the diagnosis and management of hypercholesterolemia

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Assess the evidence on the risks and benefits of new and emerging hypercholesterolemia therapies to guide treatment and management decisions for patients with statin intolerance
  • Characterize the tolerability profiles of current and emerging cholesterol-lowering agents

Disclosure of Conflicts of Interest Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

James A. Underberg, MD, MS, FACPM, FACP, FNLA
Clinical Assistant Professor of Medicine
NYU Medical School and NYU Center for CV Prevention
New York, NY

Dr. Underberg discloses the following:
Consultant/Independent Contractor: Amarin and Amgen
Grant/Research support: Aegerion and Sanofi
Advisory board honoraria: Amgen, Regeneron, Sanofi, Alexion, Akcea and Invitae
Speaker’s Bureau: Amgen, Sanofi, Regeneron, True Heath Diagnostics, Amarin and Alexion

Henry N. Ginsberg, MD
Irving Professor of Medicine
Columbia University College of Physicians and Surgeons
New York, NY

Dr. Ginsberg discloses the following:
Consultant/Independent Contractor: Amgen, Merck and Sanofi-Regeneron
Grant/Research support: Amgen, Merck and Sanofi-Regenero

Alan Brown, MD, FACC, FNLA
Director
Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, IL

Dr. Brown discloses the following:
Consultant: Amarin, Amgen, Kastle, Kowa, Pfizer and Regeneron
Speaker’s Bureau: Amgen, Regeneron and Sanofi

Michael Davidson, MD
Professor
Director of the Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, IL

Dr. Davidson discloses the following:
Consultant/Independent Contractor: Amgen, Regeneron and Sanofi
Speakers Bureau: Amgen, Regeneron and Sanofi

Accredited Provider Disclosure

Global Education Group
Planning Staff: Ashley Marostica, RN, MSN, Lindsay Borvansky, Kristen Delisi, NP, Amanda Glazar, PhD, Andrea Funk, and Laura Gilsdorf have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education
Planning Staff: David Heckard; Maryjo Dixon, RPh, Dipti Desai, PharmD, RPh, and Kathleen Bowen have no relevant financial relationships with commercial interests to disclose.

Publishing Staff Disclosures

The Physicians' Education Resource®, LLC (PER®) staff have no relevant financial relationships with commercial interests to disclose.

Credit

0.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians' Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.25

Type

CE for Nurse Practitioners

Accreditation Statement


Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 1561024

Designation Statement

This activity is accredited for 0.25 contact hour which includes 0.00 hour(s) of pharmacology.

Activity ID #2301E

This activity was planned in accordance with AANP CE Standards and Policies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Global Education Group or Physicians' Education Resource®, LLC (PER®). This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter.

Therefore, health care professionals and other individuals should review and consider other publications and materials on the subject.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

There is no fee for this educational activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue